[go: up one dir, main page]

PL2897611T3 - Sposób leczenia wirusowego zapalenia wątroby typu C - Google Patents

Sposób leczenia wirusowego zapalenia wątroby typu C

Info

Publication number
PL2897611T3
PL2897611T3 PL13773463T PL13773463T PL2897611T3 PL 2897611 T3 PL2897611 T3 PL 2897611T3 PL 13773463 T PL13773463 T PL 13773463T PL 13773463 T PL13773463 T PL 13773463T PL 2897611 T3 PL2897611 T3 PL 2897611T3
Authority
PL
Poland
Prior art keywords
methods
treating hepatitis
hepatitis
treating
Prior art date
Application number
PL13773463T
Other languages
English (en)
Inventor
Teresa NG (lok-Chan)
Tami J. Pilot-Matias
Warren M. Kati
Preethi Krishnan
Clarence J. Maring
Neeta C. Mistry
Thomas J. REISCH
Rolf Wagner
Dachun Liu
John K. Pratt
Mark A. Matulenko
Ryan G. Keddy
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2897611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of PL2897611T3 publication Critical patent/PL2897611T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13773463T 2012-09-18 2013-09-17 Sposób leczenia wirusowego zapalenia wątroby typu C PL2897611T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18
EP13773463.8A EP2897611B1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c
PCT/US2013/060103 WO2014047039A1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c

Publications (1)

Publication Number Publication Date
PL2897611T3 true PL2897611T3 (pl) 2020-03-31

Family

ID=49304326

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13773463T PL2897611T3 (pl) 2012-09-18 2013-09-17 Sposób leczenia wirusowego zapalenia wątroby typu C

Country Status (25)

Country Link
US (1) US20140080868A1 (pl)
EP (2) EP2897611B1 (pl)
JP (4) JP6297044B2 (pl)
CN (1) CN104797253A (pl)
AU (2) AU2013318302B2 (pl)
BR (1) BR112015006037B1 (pl)
CA (1) CA2884539C (pl)
CY (1) CY1122442T1 (pl)
DK (1) DK2897611T3 (pl)
ES (1) ES2755089T3 (pl)
HR (1) HRP20191939T1 (pl)
HU (1) HUE046544T2 (pl)
LT (1) LT2897611T (pl)
MX (2) MX367796B (pl)
NZ (1) NZ630581A (pl)
PL (1) PL2897611T3 (pl)
PT (1) PT2897611T (pl)
RS (1) RS59640B1 (pl)
RU (1) RU2665365C2 (pl)
SG (2) SG11201502095SA (pl)
SI (1) SI2897611T1 (pl)
SM (1) SMT201900683T1 (pl)
TW (1) TWI621436B (pl)
WO (1) WO2014047039A1 (pl)
ZA (1) ZA201501752B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2897611B1 (en) * 2012-09-18 2019-07-24 AbbVie Inc. Methods for treating hepatitis c
NZ631155A (en) * 2013-03-14 2016-05-27 Abbvie Inc Combination of two antivirals for treating hepatitis c
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CA2942823C (en) 2014-04-02 2023-01-03 Abbvie Inc. Methods for treating hcv
JP6559701B2 (ja) * 2014-04-02 2019-08-14 アッヴィ・インコーポレイテッド Hcvを処置するための方法
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CA2990855A1 (en) * 2015-06-26 2016-12-29 Abbvie Inc. Solid pharmaceutical compositions for treating hcv
HK1255481A1 (zh) * 2015-07-08 2019-08-16 Abbvie Inc. 用於治疗hcv的方法
SG10202002900YA (en) * 2015-07-17 2020-05-28 Abbvie Inc Solid pharmaceutical compositions for treating hcv
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080197A1 (es) * 2006-02-09 2008-04-11 Schering Corp Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
CH707030B1 (de) * 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
EP2897611B1 (en) * 2012-09-18 2019-07-24 AbbVie Inc. Methods for treating hepatitis c

Also Published As

Publication number Publication date
DK2897611T3 (da) 2019-11-04
JP6297044B2 (ja) 2018-03-20
NZ630581A (en) 2017-02-24
CA2884539A1 (en) 2014-03-27
EP2897611A1 (en) 2015-07-29
RU2015114543A (ru) 2016-11-10
MX367796B (es) 2019-09-06
BR112015006037B1 (pt) 2022-05-17
JP6556884B2 (ja) 2019-08-07
CY1122442T1 (el) 2021-01-27
SG11201502095SA (en) 2015-05-28
EP3597190A1 (en) 2020-01-22
MX2015003501A (es) 2015-10-26
ES2755089T3 (es) 2020-04-21
JP2021054849A (ja) 2021-04-08
SMT201900683T1 (it) 2020-01-14
HK1209319A1 (en) 2016-04-01
AU2018203608A1 (en) 2018-06-14
AU2013318302B2 (en) 2018-02-22
JP2018109035A (ja) 2018-07-12
TW201412311A (zh) 2014-04-01
SG10201702248UA (en) 2017-04-27
RS59640B1 (sr) 2020-01-31
US20140080868A1 (en) 2014-03-20
RU2665365C2 (ru) 2018-08-29
JP2015528511A (ja) 2015-09-28
LT2897611T (lt) 2019-12-10
CN104797253A (zh) 2015-07-22
ZA201501752B (en) 2016-08-31
HRP20191939T1 (hr) 2020-01-10
PT2897611T (pt) 2019-11-27
JP2019194241A (ja) 2019-11-07
HUE046544T2 (hu) 2020-03-30
AU2013318302A1 (en) 2015-04-02
SI2897611T1 (sl) 2019-12-31
CA2884539C (en) 2022-06-21
TWI621436B (zh) 2018-04-21
AU2018203608B2 (en) 2019-12-19
WO2014047039A1 (en) 2014-03-27
MX2019010600A (es) 2020-02-03
EP2897611B1 (en) 2019-07-24
BR112015006037A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
ZA201501752B (en) Methods for treating hepatitis c
IL231515A0 (en) Methods for treating hepatitis C virus
IL235062A0 (en) Compounds and methods for antiviral therapy
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
SG2014010490A (en) Combination treatments for hepatitis c
ZA201906339B (en) Methods for treating pruritus
GB201207997D0 (en) Process
GB201214326D0 (en) Process
ZA201501758B (en) Methods for treating hepatitis c
GB201213360D0 (en) Process
EP2852660A4 (en) PROCESS
ZA201406172B (en) Compounds and methods for treating leukemia
EP2854774A4 (en) METHODS OF TREATING INSOMNIA
GB201214387D0 (en) Methods for treating plants
GB201209932D0 (en) Improved process
GB201205449D0 (en) Treatment process
GB201215657D0 (en) Process
GB201215646D0 (en) Process
GB201213874D0 (en) Process
GB201211099D0 (en) Process
GB201209279D0 (en) Process
GB201205665D0 (en) Process
GB201205052D0 (en) Process